Protein
Description 25 kDa; 205 amino acids (BCL2b) or 239 amino acids (BCL2a, which has, in addition, a hydrophobic tail for membrane anchorage; this tail seems necessary for anti apoptotic ability); contain homo/heterodimerization domains (BH) and NH domains.
Expression
Wide; in B and T cells in particular.
Localisation
Mainly in the mitochondrial membrane; other membranes.
Function
Antiapoptosis, through a possibly complex process; dimerization, especially with BAX; role of the BCL2 anti-apoptosis members in forming complexes with caspase-9 and APAF1 (homolog of the nematode CED-4), which prevent them to initiate the protease cascade (through caspase-3 cytochrome C dependent activation and) leading to apoptosis.
Homology
With Ced9 (nematode C. elegans); with other member of the BCL2 family: 1-apoptosis inhibitors BCLX, MCL1, and 2-apoptosis inducers BAX, BAD, BIK, … Implicated in t(14;18)(q32;q21)/B-cell malignancies → IgH -BCL2 Disease B-cell NHL mainly; found in 80 to 90% of follicular lymphomas, 30% of diffuse large cell lymphomas. Prognosis According to the cyto-pathologic subtype: small cleaved cell follicular lymphomas have a good prognosis; large cell lymphomas have a worse prognosis; the t(14;18) may have no prognostic significance. Cytogenetics Complex karyotypes are frequent with +7, del(6q), +12, + X, … Hybrid/Mutated Gene 5' BCL2 translocated on chromosome 14 near JH (junctions genes of IgH) and C in 3'.
Abnormal Protein
No fusion protein, but promoter exchange; the immunoglobulin gene enhancer stimulates the expression of BCL2.
Oncogenesis
As BCL2 is an apoptosis inhibitor, cell death is delayed, and there is cell accumulation (more than real transformation).
Chronic lymphocytic leukaemia
Oncogenesis BCL2 is hypomethylated in the promotor region, and, therefore, overexpressed.
